Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
COMMENTARY
Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
The diabetes drug market is heating up again. Novo Nordisk Pharma’s Rybelsus (semaglutide), the first oral GLP-1 receptor agonist in Japan, was approved on June 29, while a number of insulin combination products and biosimilars have been launched as well.…
To read the full story
Related Article
- Chugai, Sanofi Wind Up License Deal for Apleway; Kowa to Get MA
February 18, 2020
- MSD to Transfer Japan Distribution Rights for DPP-4 Inhibitor Marizev to Kissei
February 4, 2020
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
- Taisho, Novartis to Stop Comarketing Lusefi at December-End
October 31, 2019
COMMENTARY
- Supply Woes Plague All 7 New Biosimilar Ingredients Listed since 2023
November 16, 2026
- Japan Drug Wholesalers Caught in Multiple Dilemmas as Price Gap Narrows
November 10, 2026
- Deeper CEA Price Cuts Demand More Than a “Certain Degree of Validity”
November 2, 2026
- Alzheimer’s Pipeline Looks Past Amyloid to Earlier Intervention, Tau Targets
October 28, 2026
- Lp(a) Drugs Face Next Test in Quest to Cut Cardiovascular Risk
October 19, 2026





